leisure time -WSS

leisure time

author：fashion 2025-09-30 22:55:04 - browse：24

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： How state and local governments are sidelining science

WSS

Mindstrong's demise and the future of mental health care

Covid vaccines: Private market messier than government rollout

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

After decades in use, heart stents finally beat placebo

Medicaid, Medicare dual

Kaiser Permanente unions announce official strike date

leisure time

leisure time

Wikipedia

Psychedelics group wrestles with new pharma identity

Medicare drug price negotiation program allowed for now

Tori Bowie and the unacceptable rates of Black maternal death

Carbon Health diabetes program, a test of data

Supreme Court strikes down use of affirmative action

STAT Virtual Event: How to Increase Diversity in Clinical Trials

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A letter from the executive editor: STAT UnitedHealth investigation

How one medical school became remarkably diverse

Data show record exodus of life scientists from academia

knowledge

FDA seeks to regulate lab

How state and local governments are sidelining science

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Data show record exodus of life scientists from academia

Readout Newsletter: Zepbound, Valneva's vaccine, and more

explore

focus

hotspot

focus